These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 2141779)

  • 1. Age-related differences in pharmacokinetics of phosphonoformate in cats.
    Swenson CL; Sams RA; Polas PJ; Michael DF; Mathes LE
    Antimicrob Agents Chemother; 1990 May; 34(5):871-4. PubMed ID: 2141779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of potential anti-AIDS agents thiofoscarnet and foscarnet in the cat.
    Straw JA; Loo TL; de Vera CC; Nelson PD; Tompkins WA; Bai SA
    J Acquir Immune Defic Syndr (1988); 1992; 5(9):936-42. PubMed ID: 1387417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age-related differences in phosphonoformate-induced bone toxicity in cats.
    Swenson CL; Weisbrode SE; Nagode LA; Hayes KA; Steinmeyer CL; Mathes LE
    Calcif Tissue Int; 1991 May; 48(5):353-61. PubMed ID: 1829019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Body burden" of phosphonoformic acid after topical and vaginal administration to rabbits and beagle dogs.
    Hussain AS; Ritschel WA
    Methods Find Exp Clin Pharmacol; 1989 Feb; 11(2):111-4. PubMed ID: 2523506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of PFA (trisodium phosphonoformate) after i.v. and p.o. administration to beagle dogs and rabbits.
    Ritschel WA; Grummich KW; Hussain SA
    Methods Find Exp Clin Pharmacol; 1985 Jan; 7(1):41-8. PubMed ID: 3157841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphonoformate inhibits reverse transcriptase.
    Sundquist B; Oberg B
    J Gen Virol; 1979 Nov; 45(2):273-81. PubMed ID: 94344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis.
    Aweeka F; Gambertoglio J; Mills J; Jacobson MA
    Antimicrob Agents Chemother; 1989 May; 33(5):742-5. PubMed ID: 2546491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic and therapeutic effects of phosphonoformate against feline leukemia virus in vitro.
    Swenson CL; Polas PJ; Cheney CM; Kociba GJ; Mathes LE
    Am J Vet Res; 1991 Dec; 52(12):2010-5. PubMed ID: 1724122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral effects of phosphonoformate (PFA, foscarnet sodium).
    Oberg B
    Pharmacol Ther; 1989; 40(2):213-85. PubMed ID: 2543994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Encapsulation of foscarnet in liposomes modifies drug intracellular accumulation, in vitro anti-HIV-1 activity, tissue distribution and pharmacokinetics.
    Dusserre N; Lessard C; Paquette N; Perron S; Poulin L; Tremblay M; Beauchamp D; Désormeaux A; Bergeron MG
    AIDS; 1995 Aug; 9(8):833-41. PubMed ID: 7576316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus.
    Sjövall J; Karlsson A; Ogenstad S; Sandström E; Saarimäki M
    Clin Pharmacol Ther; 1988 Jul; 44(1):65-73. PubMed ID: 2968875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No in vivo effect of trisodium phosphonoformate on woodchuck hepatitis virus production.
    Nordenfelt E; Widell A; Hansson BG; Löfgren B; Möller-Nielsen C; Oberg B
    Acta Pathol Microbiol Immunol Scand B; 1982 Dec; 90(6):449-51. PubMed ID: 6220563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of hepatitis-B-virus DNA polymerase by phosphonoformate: studies on its mode of action.
    Hess G; Arnold W; Meyer zum Büschenfelde KH
    J Med Virol; 1980; 5(4):309-16. PubMed ID: 6453206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral effects of phosphonoformate (PFA, foscarnet sodium).
    Oberg B
    Pharmacol Ther; 1982; 19(3):387-415. PubMed ID: 6201932
    [No Abstract]   [Full Text] [Related]  

  • 15. Alkylthioglycerol prodrugs of foscarnet: synthesis, oral bioavailability and structure-activity studies in human cytomegalovirus-, herpes simplex virus type 1- and human immunodeficiency virus type 1-infected cells.
    Beadle JR; Kini GD; Aldern KA; Gardner MF; Wright KN; Richman DD; Hostetler KY
    Antivir Chem Chemother; 1998 Jan; 9(1):33-40. PubMed ID: 9875375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid prodrugs of phosphonoacids: greatly enhanced antiviral activity of 1-O-octadecyl-sn-glycero-3-phosphonoformate in HIV-1, HSV-1 and HCMV-infected cells, in vitro.
    Hostetler KY; Kini GD; Beadle JR; Aldern KA; Gardner MF; Border R; Kumar R; Barshak L; Sridhar CN; Wheeler CJ; Richman DD
    Antiviral Res; 1996 Jun; 31(1-2):59-67. PubMed ID: 8793009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of trisodium phosphonoformate and idoxuridine on experimental herpes simplex keratitis in immunized and non-immunized rabbits.
    Alenius S; Laurent U; Oberg B
    Acta Ophthalmol (Copenh); 1980 Apr; 58(2):167-73. PubMed ID: 6249066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the DNA polymerases induced by a group of herpes simplex virus type I variants selected for growth in the presence of phosphonoformic acid.
    Derse D; Bastow KF; Cheng Y
    J Biol Chem; 1982 Sep; 257(17):10251-60. PubMed ID: 6286645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacology: foscarnet.
    Lietman PS
    Am J Med; 1992 Feb; 92(2A):8S-11S. PubMed ID: 1371039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphonoformate (foscarnet): a pilot study in AIDS and AIDS related complex.
    Farthing CF; Dalgleish AG; Clark A; McClure M; Chanas A; Gazzard BG
    AIDS; 1987 May; 1(1):21-5. PubMed ID: 2962589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.